Stocks analysis

A vs AFL Stock Comparison

Scores Breakdown

Metric A AFL
📈 Growth 18/30 6/30
💰 Profitability 16/20 10/20
🏦 Financial Health 7/20 18/20
💵 Valuation 9/20 14/20
⚠️ Risk (lower is better) 7/10 6/10
Overall Score 53/100 52/100

Side-by-Side Summaries

A Analysis AFL Analysis

📈 Growth & Financial Trajectory

Over eight quarters, Revenues rose from about $1.66B to $1.84B, a positive trend, with a mid-2025 dip. Net income fluctuated from $308M–$434M, ending near $339M in 2026 Q2. The sequence shows top-line resilience but earnings volatility, implying improving mix or cost management but not a steady uplift in profitability.

💰 Margins & Cash Flow

  • Gross Margin is generally in the mid-50s percentile, peaking around 63% in 2024 Q2 and typical ~50–55% in other quarters.
  • Operating Margin has run in the high-teens to low-20s percent range on Revenues of ~$1.6–$1.8B.
  • Operating cash flow remains positive across quarters (roughly $0.27–$0.55B), while investing cash flow is negative (capital outlays), and financing cash flow is often negative, reflecting debt/return actions.

🛡️ Balance Sheet & Liquidity

Total Assets ($11–$13B) exceed Liabilities ($4.8–$6B) with Equity frequently negative, signaling balance-sheet rehabilitation needs. Current assets vs current liabilities suggests solid liquidity (working capital positive); long-term debt remains a meaningful load but generally manageable within cash flows.

⚠️ Key Drivers & Risks

  • Drivers: Life sciences capex & instrument upgrades; continued demand for laboratory testing and automation.
  • Risks: Earnings volatility from cyclic lab-spend; structural negative equity raises valuation sensitivity and balance-sheet risk.

📈 Growth & Financial Trajectory

The eight quarterly results show a mixed growth path. Start: revenues of $5.138B in 2024 Q2 and end: $4.346B in 2026 Q1, a decline of about 15%. Net income moved from $1.755B in 2024 Q2 to $1.019B in 2026 Q1, down roughly 42%. Notable quarter-to-quarter swings include a robust Q4 2024 and steady early-2025 quarters, but the overall trend is inconsistent, with revenue occasionally bouncing on seasonal/one-offs while earnings remain volatile. Operating income remained strong in several periods (around $3.0–$3.4B on mid-single to low-double-digit revenue), suggesting earnings power when volume picks up, but not a clear, sustained growth trajectory.

💰 Margins & Cash Flow

Margins vary meaningfully by quarter; reported operating income margins range widely, reflecting unusual items and mix. Net cash from operating activities was solid in several quarters (e.g., $589M in 2025 Q1 and $968M in 2026 Q1) but softer in others (e.g., $315M in 2025 Q4). Investing and financing activities can create negative free cash flow in some periods, yielding an uneven cash flow signal despite positive operating cash in many quarters.

🛡️ Balance Sheet & Liquidity

Assets typically sit around $116–$122B, with Liabilities in the $86–$93B range and Equity near $26–$30B, indicating reasonable leverage and strong liquidity. The structure supports resilience across varying earnings seasons, though reported items occasionally show anomalies in current liabilities.

⚠️ Key Drivers & Risks

  • Drivers: Interest-rate environment; demand for life/health insurance and annuities.
  • Risks: Earnings volatility from taxes and one-offs; potential margin compression and inconsistent free cash flow.

Top Rated Companies

View Top 20 →
MU "MICRON TECHNOLOGY INC"
89
AVGO "Broadcom Inc."
89
KMI "KINDER MORGAN, INC."
87
MNST "Monster Beverage Corp"
87
NEM "NEWMONT Corp /DE/"
87